Mind the metal: a fragment library-derived zinc impurity binds the E2 ubiquitin-conjugating enzyme Ube2T and induces structural rearrangements by Morreale, Francesca E. et al.
 
 
 
 
 
Morreale, F. E., Testa, A., Chaugule, V. K., Bortoluzzi, A., Ciulli, 
A. and Walden, H.  (2017) Mind the metal: a fragment library-derived zinc 
impurity binds the E2 ubiquitin-conjugating enzyme Ube2T and induces 
structural rearrangements. Journal of Medicinal Chemistry, 60(19), pp. 
8183-8191. (doi:10.1021/acs.jmedchem.7b01071 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/149792/                                                                                                          
 
 
 
 
 
 
Deposited on: 23 October 2017 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 1 
Mind the metal: a fragment library-derived zinc 
impurity binds the E2 ubiquitin-conjugating enzyme 
Ube2T and induces structural rearrangements  
Francesca E. Morreale,1 Andrea Testa,2 Viduth K. Chaugule,1 Alessio Bortoluzzi,2               
Alessio Ciulli,2* Helen Walden,1*  
1 MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of 
Dundee, Dundee DD1 5EH, United Kingdom 
2 Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of 
Dundee, Dundee DD1 5EH, United Kingdom 
KEYWORDS. Ubiquitin-conjugating enzymes, domain swap, false positives, metal-induced 
oligomerization, ubiquitination, X-ray crystallography 
  
 2 
ABSTRACT  
Efforts to develop inhibitors, activators and effectors of biological reactions using small 
molecule libraries are often hampered by interference compounds, artifacts and false positives 
that permeate the pool of initial hits. Here we report the discovery of a promising initial hit 
compound targeting the Fanconi anemia ubiquitin-conjugating enzyme Ube2T and describe its 
biophysical and biochemical characterization. Analysis of the co-crystal structure led to the 
identification of a contaminating zinc ion as solely responsible for the observed effects. Zinc 
binding to the active site cysteine induces a domain swap in Ube2T that leads to cyclic 
trimerization organized in an open ended linear assembly. Our study serves as a cautionary tale 
for screening small molecule libraries and provides insights into the structural plasticity of 
ubiquitin-conjugating enzymes. 
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INTRODUCTION 
 
Many different mechanisms can lead to false positive signals when screening for small 
molecules binding to a protein of interest. Among them are compound aggregation, interference 
with the detection method, covalent and nonspecific crosslinking, redox reactions or presence of 
impurities.1 Several molecules that yield false signals across different assays are known as 
PAINS (pan-assay interference compounds). Such compounds have defined structures and are 
repeatedly identified and published as promising hits against different proteins, however their 
activity does not depend on specific, drug-like interactions with the protein, and instead arise as 
the result of a variety of artifacts.2 Some types of false positives are easier to detect and discard. 
For instance, using orthogonal assays is a common way to exclude interferences related to a 
particular detection method and using non-ionic detergents can effectively relieve enzyme 
inhibition by aggregated compounds.3 In other cases, compound interference can be more 
difficult to recognize, especially when the observed effect is concentration dependent and 
consistent across different orthogonal assays. 
 
We recently reported a fragment screening against the ubiquitin-conjugating enzyme Ube2T.4 
Ubiquitin-conjugating enzymes (E2s) possess a catalytic cysteine, which receives a ubiquitin 
molecule from the E1 (ubiquitin-activating enzyme) through a transthiolation reaction and, 
together with an E3 ligase, transfers it onto the lysine of a substrate. All E2s possess a core 
catalytic domain (~150 amino acids), known as UBC (ubiquitin-conjugating) fold that contains a 
conserved catalytic cysteine (Figure 1A). This domain is normally composed of four α helices 
and four β strands, occasionally enriched by insertion loops and N- or C-terminal extensions, 
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which are often intrinsically disordered.5, 6 RING-type E3s facilitate ubiquitin transfer by binding 
the E2s on a surface that is distinct from the active site.7, 8 This region comprises loops 1 and 2 
and the first α helix of the UBC fold.  
Ube2T shares the canonical UBC fold and presents a C-terminal extension (~ 40 residues), 
which is not visible in any of the published crystal structures.4, 9, 10 Ube2T specifically interacts 
with the RING E3 ligase FANCL with a KD of ∼0.5 μM.10, 11 This exclusive E2-E3 pair catalyzes 
the monoubiquitination of the heterodimeric FANCI/FANCD2 complex, which is the key 
signaling event to activate the Fanconi anemia pathway for DNA repair.12, 13 
 
Here we report the detailed biophysical characterization and optimization attempts for what 
seemed to be the most promising hit compound of our fragment screening. The effects of this 
molecule were consistent and concentration dependent across a wide range of biophysical assays. 
Puzzlingly, most of the synthesized analogues resulted in complete loss of binding, even when 
modifications were minor. The crystal structure was crucial for explaining the lack of a 
consistent structure-activity relationship (SAR): the effects of our hit compound were solely due 
to a zinc contamination. Zinc induces an unprecedented arrangement in Ube2T by binding at two 
different sites on the protein: the first site mediates the formation of a domain swapped cyclic 
trimer, and the second site is responsible for the arrangement of the trimers in an open-ended 
linear assembly. Our study shows that the active site cysteine in Ube2T is susceptible to 
modification and reveals the plasticity of the E2 fold. 
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RESULTS AND DISCUSSION 
 
Discovery of compound 1 as a potential Ube2T inhibitor 
Compound 1 (Figure 1B) was identified as a hit in our recently published fragment screening 
against the ubiquitin-conjugating enzyme Ube2T.4 The initial orthogonal screens using 
differential scanning fluorimetry (DSF) and bio-layer interferometry (BLI) both yielded 
compound 1 as a very promising hit showing a concentration dependent effect (Figure S1). 
Although compound 1 acted as a destabilizer in DSF, causing a decrease in Ube2T’s melting 
temperature (even at low concentrations), we pursued this due to reports that destabilizing agents 
can be confirmed as true binders.4, 14 In BLI, association and dissociation responses were 
observed also at the lowest concentration tested (2 μM), in contrast with other fragments which 
didn’t show any binding at this concentration.  
Having identified 1 as the most potent hit of our fragment screening, we were interested in 
characterizing it further and exploring its mechanism of action.  
In order to map its binding site, we performed HSQC experiments using 15N-labeled Ube2TΔC 
(residues 1-154, lacking the C-terminal flexible tail).4 Upon addition of increasing compound 1 
concentrations (100 μM, 300 μM and 500 μM), several resonance peaks became weaker and 
finally disappeared when an approximate 1:10 molar ratio was reached (500 μM 1, Figure S2). 
Disappearance of the peaks suggested a tighter interaction of 1 compared to the other fragments 
tested, that only caused moderate shifts at millimolar concentrations. We confirmed that 
disappearance of the peaks was due to a genuine and reversible binding by dialyzing out 
compound 1 overnight. As expected, the signals’ position in the free spectrum was restored after 
dialysis. These residues were mapped onto the available Ube2T crystal structures4, 9, 10 and 
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appeared to be adjacent to the catalytic cysteine (Figure 1C). At this site however, no apparent 
pocket was present. We therefore speculated that a structural rearrangement needed to occur to 
accommodate a small molecule binding.  
In order to obtain more insights into compound 1 binding, we performed isothermal titration 
calorimetry (ITC) experiments (Figure 1D and Table S1) and found that 1 binds Ube2T with a 
KD = 17.7 μM (LE = 0.41 kcal mol–1), a rather high affinity for a fragment. 
In order to assess whether the binding of 1 was competitive with that of Ube2T cognate E3, we 
used a different construct in which Ube2T is fused to the RING domain of FANCL through a 
linker between the two proteins (Ube2T-FANCLRING).
10 A similar KD was obtained when 1 was 
titrated against the Ube2T-FANCLRING fusion protein (Figure 1D), confirming that 1 binds to a 
different site. In contrast, binding was completely lost when Ube2T carries a ubiquitin molecule 
at the active site (Ube2T-Ub, where ubiquitin is linked through an isopeptide bond to the C86K-
K91R-K95R mutant Ube2T). This was consistent with the observation that the compound 1 
binding site is adjacent to the catalytic cysteine (C86). We next investigated if 1 was able to 
affect Ube2T enzymatic activity using a biochemical assay. This assay monitors the first step of 
the ubiquitination cascade, which is the ability of Ube2T (the E2) to be ubiquitin-charged by the 
E1 on the catalytic cysteine via a transthiolation reaction. As shown in Figure 1E, in the absence 
of compound 1, Ube2T is charged and autoubiquitinates itself as previously reported.12 Addition 
of 100 μM 1 almost completely abolished Ube2T charging and this effect was concentration-
dependent. In contrast, the same concentrations did not affect the E1-Ub charging in the absence 
of Ube2T (Figure 1E), indicating that 1 specifically inhibits Ube2T-Ub charging by the E1. 
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These results, together with the biophysical characterization reported above, suggested that 1 
was a very encouraging hit compound able to compromise the catalytic activity of Ube2T, 
therefore suitable for further optimization. 
 
 
Figure 1. Biophysical and biochemical characterization of compound 1. (A) Ube2T structure 
showing the typical E2 UBC fold. (B) Chemical structure of 1. (C) 1 binding site determined by 
protein-observed NMR and mapped on Ube2T crystal structure. Residues colored in magenta 
correspond to 15N-Ube2T HSQC resonances affected by the addition of 1 (see also Figure S2). 
(D) ITC titrations of 1.5 mM 1 against ~50 μM of the different Ube2T constructs indicated, 
details are reported in Table S1. (E) Representative coomassie stained gel of the biochemical 
assay monitoring the ubiquitin-charging of Ube2T in presence of compound 1. The left lanes 
show a control reaction in which Ube2T is absent. 
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Synthesis of compound 1 analogues 
In order to optimize the binding affinity of compound 1, we set up crystallization experiments 
aimed to determine the mode of binding of 1. In parallel, we designed a small library of 
compounds (2-14) to begin to evaluate structure activity relationships (Chart 1).  
 
 
 
Chart 1. Chemical structure of compound 1 analogues. Derivatives 1, 2, 3, 5, 6, 8, 9, 12 were 
purchased from a commercial vendor. 4, 7, 10, 11, 13, 14 were synthesized. 
 
First, the amidine moiety was removed or replaced by a primary amine, an amide or a 
carboxylate (derivatives 2-6). Compounds 2, 3, 5, 6 and 7 were commercially available. Amide 4 
was prepared from commercially available carboxylic acid 3 and ammonium chloride by 
HATU/N,N-diisopropylethylamine (DIPEA) mediated amide coupling.  None of the compounds 
showed binding in ITC and DSF, suggesting that the amidine group is an essential feature for 
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binding. Different analogues were subsequently designed maintaining the amidine functionality 
intact and introducing modifications in the biaryl part of the molecule (Chart 1).  
Non-commercially available amidines 10-11 were synthetized in house (Scheme 1) from 6-
fluoronicotinonitrile 15 which was reacted with the appropriate pirrolidine and DIPEA in 
acetonitrile at 90 °C overnight, obtaining nitriles 16-17 in good yields after flash column 
chromatography purification. Nitriles 16-17 were treated with an excess of anhydrous gaseous 
hydrochloric acid in methanol to obtain imino ether hydrochlorides, which were treated with 7 M 
ammonia solution in methanol to obtain amidines 10-11 (50-65% yield after preparative 
HPLC).       
Nitriles 18-20 were reacted with sodium methoxide in methanol at room temperature (Scheme 
1) until full conversion to the corresponding imino ethers was observed by LC-MS. Reaction of 
the imidates (not isolated) with ammonium chloride afforded the expected amidines 7, 13 and 14, 
which were finally purified by HPLC.  
Compounds 7-14 were tested in DSF and ITC, and surprisingly only derivatives 9 and 13 
showed a concentration dependent effect in DSF (Figure S3). Only for compound 9 the KD was 
measurable by ITC, although the affinity is much weaker (~ 500 μM). Compound 13 lacks the 
two methyl groups on the pyrazole ring, whereas 9 has a saturated pyrrolidine ring replacing the 
pyrazole. However, when the pyrrolidine moiety is 2- or 3- methyl substituted (derivatives 10 
and 11), or when it is replaced by a piperidine ring (compound 12), binding is again completely 
abolished.  
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Scheme 1. Synthesis of amidines 7, 10, 11, 13 and 14. 
 
Co-crystal structure reveals a metal mediated oligomer 
The rather flat SAR results raised some concerns regarding compound 1. Although quality 
control documents were provided by the commercial vendor, we repeated NMR and HRMS 
analyses, finding them in agreement with the declared structure (see Supplementary 
Information). Despite having identified the binding site by protein-observed NMR and confirmed 
it with solid binding data, yet the molecular details of compound 1 - Ube2T interaction were 
missing. Only a co-crystal structure could help in understanding why any minor change of the 
original compound 1 structure led to a complete loss in binding. For this reason, we pursued 
multiple co-crystallization attempts using different Ube2T constructs, including the full-length 
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protein (1-197), Ube2TΔC (1-154) and the Ube2T-FANCLRING fusion construct.
10 After many 
unsuccessful attempts, well-diffracting crystals of Ube2TΔC with compound 1 in a 1:5 molar ratio 
were eventually obtained. We solved the crystal structure at 1.85 Å (PDB ID: 5OJJ, Table S2) 
and discovered an unexpected arrangement of Ube2T molecules.  
Contrary to all the other Ube2T structures in which Ube2T is monomeric (Figure 1A), our 
crystal structure contains six molecules in the asymmetric unit organized in two cyclic trimers 
(Figure 2). Each monomer has adopted an unusual conformation whereby the N-terminal α1-
helix and β1-strand (first ~ 30 residues) have moved onto the nearby molecule of the trimer with 
a cyclic organization (chain A onto B, chain B onto C, chain C onto A, Figure 2A, B). This 
structural rearrangement is called ‘domain swap’: protein molecules exchange secondary 
structure elements to form an intertwined oligomer in which the overall fold of each monomer is 
maintained, with the exception of the hinge loop connecting the part that is exchanged.15 In our 
structure the hinge loop is formed by residues Q26-D33. Interestingly, a domain swap of the 
same secondary structure elements has also been observed for a different E2, Ube2W (PDB entry 
2A7L).9 Ube2W however, forms a reciprocal dimer instead of a cyclic trimer (Figure S4). 
Close analysis of the refined structure revealed that no organic molecule corresponding to 
compound 1 structure was bound to the protein at the catalytic site as suggested by the HSQC 
experiments, or anywhere else on the surface. However a strong and unexplained density, which 
suggested a metal ion, was connected to the catalytic cysteine (C86) (Figure S5 and S6). Given 
the coordination geometry and the nature of the chelating residues, we modeled a zinc ion. The 
tetrahedral coordination is completed by the S atom of C86, the ε amino group of K91, an acetate 
molecule from the crystallization buffer and by the π nitrogen of H150 from a different Ube2T 
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molecule (Zinc site 1, Figure 2B). This zinc chelation involving two different Ube2T monomers 
is responsible for the formation of the domain swapped cyclic trimer (Figure 2B, D).  
Interestingly, when the trimer is formed, D127 residues from each Ube2T monomer come 
close together and chelate another Zn2+ ion through one oxygen atom of the carboxylate, further 
stabilizing the trimer assembly. At this second Zn2+ binding site (Zinc site 2, Figure 2C), the 
tetrahedral coordination is completed by the τ nitrogen of H12 from a different trimer, leading to 
an open ended linear assembly of trimers (Figure 2D, E). 
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Figure 2. Zinc-mediated Ube2TΔC oligomerization. (A) Comparison between the usually 
observed Ube2T monomeric structure and the domain-swapped form. (B) Structure of the 
domain-swapped cyclic trimer held together by Zn2+ ions (PDB ID 5OJJ). The domain swap 
involves helix α1 and strand β1 of the three subunits. Each monomer binds a Zn2+ ion at the 
catalytic cysteine (Zinc site 1), connecting two monomers. (C) A second zinc binding site (Zinc 
site 2) is formed on the trimer by residues D127 of each of the three subunits, and is responsible 
for joining the trimers, with H12 from a different trimer completing the tetrahedral coordination. 
(D) Schematic representation of the zinc-induced domain swap and oligomerization. (E) Surface 
representation of the open-ended linear assembly of Ube2TΔC trimers. 
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Investigating zinc contamination in our compound series 
In our structure, four zinc ions are bound to each Ube2T trimer, however no zinc salt is present 
in the crystallization buffer or is used during Ube2T expression and purification. Moreover, 
while performing co-crystallization trials, we noticed a direct correlation between compound 1 
concentration and the number of crystals formed, with no crystallization occurring when 1 was 
absent. These observations led us to hypothesize that zinc may be present as a contaminant of the 
purchased compound 1 powder, and that the observed biophysical and biochemical effects of 1 
could be attributed to the presence of zinc. To test this hypothesis we repeated the ITC 
experiments in presence of a chelating agent. Remarkably, no binding was observed in presence 
of 2 mM EDTA in the ITC buffer (Figure 3A), confirming that the exceptionally good activity of 
compound 1, found during our fragment screening, is exclusively due to zinc contamination of 
the original powder.  
Furthermore, when ZnCl2 was titrated against Ube2T in ITC, the isotherm was almost identical 
to the one obtained for compound 1 (Figure 3A). 
To further confirm the presence of zinc, we used a colorimetric reagent known as Zincon (2-
carboxy-2’-hydroxy-5’-sulfoformazylbenzene), which has been used as a chromophore for the 
quantification of both zinc and copper ions in aqueous solution.16 Zincon confirmed the presence 
of different amount of Zn2+ in compounds 1, 9 and 13 (Figure 3B, 12 was used as negative 
control), proportional to their ‘potency’ in DSF and ITC, ultimately explaining the flat and 
curious SAR of this compound series. 
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Figure 3. Confirmation of zinc contamination and binding effect. (A) The superposition of 
ZnCl2 and 1 titration against Ube2T shows an almost identical profile. Binding is lost when 1 is 
titrated against Ube2T in presence of EDTA. (B) Zincon colorimetric assay performed on 
compounds 1, 9, 13 and 12 shows correlation between the amount of zinc present and the 
observed binding potency. Water and ZnCl2 are used as references for the observed color 
changes. 
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SUMMARY AND CONCLUSIONS 
 
False positives are known to permeate the initial pool of hits from many compound screenings. 
To mitigate this effect, multiple assays are often performed in parallel to identify genuine binders 
and exclude interferences related to a single detection method, effects that can arise from 
aggregation, or covalent and non-specific crosslinking. In this context, our compound 1 case was 
particularly challenging. We detected binding in DSF and BLI, where we observed a rather 
normal association and dissociation profile. We mapped the binding site through protein-
observed NMR spectroscopy and we measured the binding affinity by ITC. Through ITC we 
were also able to estimate the stoichiometry of interaction, which appeared to be close to 1, as 
one would expect from a genuine binder. Compound 1 binding resulted in inhibition of Ube2T 
enzymatic activity, as demonstrated using a biochemical assay. All these results obtained for 
compound 1 were concentration dependent and consistent, until the unusual SAR raised the first 
suspicions. At last, only the crystal structure could tell us what was the real ‘active ingredient’ of 
our powder, which was not detectable through routine LC-MS and NMR quality control.  
Our story serves as a cautionary tale for screening small molecules libraries, in particular when 
trying to target ubiquitin-conjugating enzymes (or cysteine containing enzymes in general). 
Hermann et al. have also reported that zinc and other metal impurities, often derived from the 
synthetic procedures, may affect a number of targets or assays.17 The effect of contaminating 
metals can be recognized by repeating certain assays in presence of chelating agents (such as 
EDTA), when this is compatible with the assay setup and the protein structure (e.g. chelating 
agents should be avoided when structural or catalytic metals are part of the protein of interest). 
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In our study, the unexpected structural arrangement induced by zinc opens up new prospects. 
Although the micromolar affinity of Zn towards Ube2T excludes a physiological relevance of 
this interaction, analysis of the zinc-induced oligomerization may provide an interesting model 
for designing metal mediated protein-protein interactions. Indeed, work from several research 
groups has been focused on controlling proteins self-assembly into polymeric architectures by 
designing metal binding sites,18-21 which add strength directionality and selectivity to the 
interaction, as metal chelation geometries and preferences are well understood.22  
Another important feature of our structure is the domain swap of the N-terminal α1-helix and 
β1-strand of Ube2T, which is also observed for a different E2, Ube2W.9 Previous studies have 
indeed highlighted that the swaps adopted by members of a protein family are characteristic traits 
of the protein fold.23, 24 Domain swap has been often associated with a high degree of structural 
plasticity, as an example, GB1 protein (immunoglobulin-binding domain B1 of streptococcal 
protein G) has been named ‘protein contortionist’ for its ability to form a swapped dimer, a 
tetramer, or an amyloid fibril upon mutation of specific residues.25-27 
Although the biological role of protein domain swapping remains elusive, it has attracted much 
interest because of its potential involvement in protein misfolding and aggregation processes 
associated with amyloid formation and prion diseases.28-30  
Different mechanisms have been proposed for the monomer to oligomer transition. These 
include formation of an ‘open’ intermediate, or a transition in which conformational changes of 
individual monomers and their association are tightly coupled to minimize solvent exposure.24 
Another hypothesis is the formation of an unfolded state prior to oligomer assembly. Irrespective 
of the domain swap, different changes in the environmental conditions (pH, temperature, salt 
ions) may destabilize the monomeric folded state of a protein and trigger aggregation.31 In our 
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system, we observed significant destabilization of Ube2T in presence of zinc, with decrease of 
the protein unfolding temperature in DSF. We therefore hypothesize that zinc binding at the 
catalytic cysteine promotes the domain swap either by an allosteric mechanism or by inducing an 
intermediate unfolded state. The observed structural plasticity for Ube2T and Ube2W, together 
with the induced allosteric effect across the UBC fold proposed here for Ube2T, might emerge as 
a common characteristic for the ubiquitin-conjugating enzyme family. 
 
 
EXPERIMENTAL SECTION 
 
 Protein Expression and purification 
All the Ube2T constructs were expressed and purified as described previously.4, 10 In order to 
generate a stable ubiquitin-loaded Ube2T, the catalytic cysteine was mutated to a lysine (C86K) 
and the two lysines close to the catalytic site were mutated to arginines (K91R and K95R). 
Ubiquitin was then enzymatically linked to K86 through an isopeptide bond between ubiquitin 
C-terminus and the ε amino group of K86, as described by Plechanovová et al.32 
 
 Fragment screening 
Our fragment screening cascade consisted of a combination of biophysical methods. DSF, BLI 
and protein-observed NMR were performed as described previously.4 However, for DSF and 
HSQC experiments, lower compound concentrations were used compared to the other fragments 
reported in our previous study.4 For the DSF experiments, 40 μL samples were prepared in 
duplicates using 5 μM Ube2T, 2.5x SYPRO orange in 100 mM Tris pH 8.0, 100 mM NaCl, 0.25 
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mM TCEP and a compound concentration ranging from 5 μM to 5 mM. The samples were 
heated from 25 °C to 95 °C with increments of 1 °C/minute, and fluorescence was measured at 
each step. Data analysis was performed as described by Niesen et al.33  
 Nuclear Magnetic Resonance Spectroscopy 
[1H–15N]-HSQC spectra were recorded on 50 μM 15N-Ube2TΔC with increasing compound 1 
concentration (100 μM, 300 μM and  500 μM) as described previously.4 A superposition of the 
apo-protein spectrum with the spectrum recorded at the highest compound 1 concentration tested 
is shown in Figure S2. Compound 1 was then dialyzed out overnight in the same buffer used for 
the described NMR experiments (50 mM Potassium phosphate pH 6.8, 85 mM NaCl, 1 mM 
DTT). After dialysis a new HSQC spectrum was recorded, showing that the signals position in 
the apo Ube2T spectrum was restored.  
 
 Isothermal Titration Calorimetry 
All the experiments were carried out using the MicroCal PEAQ-ITC (Malvern) and analyzed 
using the MicroCal PEAQ-ITC Analysis Software. All the titrations were performed at 25 °C, 
whilst stirring at 750 rpm in a buffer containing 100 mM Tris pH 8.0, 100 mM NaCl, 0.5 mM 
TCEP. A control experiment of titrant into buffer was performed in order to account for the heat 
of dilution. All the titrations were repeated at least twice with similar results. For all the titrations 
an approximate protein concentration of 50 μM was used. Detailed concentrations and 
thermodynamic parameters per each fitted ITC experiment are reported in Table S1. 
 
 Ube2T charging assay 
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Ube2T charging reactions (20 μl) contained 20 μM ubiquitin, 0.2 μM of recombinant human 
E1, 10 μM Ube2T and 5 mM ATP. Reactions were carried out for 10 minutes at 30 °C and 
terminated with non-reducing LDS loading buffer. The samples were resolved by SDS-PAGE 
and coomassie stained (Figure 1E). All the experiments were repeated at least twice with similar 
results. 
 
 Synthetic procedures 
All chemicals, unless otherwise stated, were commercially available and used without further 
purification. Reactions were magnetically stirred; commercially available anhydrous solvents 
were used. Flash column chromatography (FCC) was performed using a Teledyne Isco 
Combiflash Rf or Rf200i, prepacked columns RediSep Rf Normal Phase Disposable Columns 
were used. NMR spectra were recorded on a Bruker Ascend 400. Chemical shifts are quoted in 
ppm and referenced to the residual solvent signals: 1H δ = 7.26 ppm (CDCl3), 4.79 ppm (D2O), 
2.50 ppm (DMSO-d6), 
13C δ = 77.2 ppm (CDCl3), 39.5 ppm (DMSO-d6); signal splitting patterns 
are described as singlet (s), doublet (d), doublet of doublet (dd), triplet (t), quartet (q), multiplet 
(m), broad (br). Coupling constants (JH–H) are measured in Hz. High resolution mass spectra 
(HRMS) were recorded on a Bruker microTOF. Low resolution MS and analytical HPLC traces 
were recorded on an Agilent Technologies 1200 series HPLC connected to an Agilent 
Technologies 6130 quadrupole LC–MS, connected to an Agilent diode array detector. 
Preparative HPLC was performed on a Gilson preparative HPLC system with a Waters X-Bridge 
C18 column (100 mm × 19 mm; 5 μm particle size). Elution conditions are reported in the 
general methods. The purity of all compounds was analyzed by HPLC–MS (ESI) and was >95%. 
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6-(3,5-dimethyl-1H-pyrazol-1-yl)nicotinamide (4).  To a solution of 3 (20 mg, 0.092 mmol) in 
DMF (4 mL), HATU (53 mg, 0.138 mmol), NH4Cl (10 mg, 0.184  mmol) and DIPEA (63 µL, 
0.368 mmol) were added. The reaction mixture was stirred at room temperature for 3 hours, the 
solvent was then removed under reduced pressure. The crude was dissolved in DCM (5 mL) and 
washed with water (2 mL) and the organic layer was dried over anhydrous MgSO4. DCM was 
removed under reduced pressure and the crude was dissolved in methanol and purified by 
preparative HPLC (gradient of 5–95% acetonitrile in water with 0.1% formic acid over 10 min, 
flow 25 mL/min) and freeze-dried to obtain the title compound as a white powder, 12 mg, 60% 
yield. ¹H NMR (400 MHz, DMSO) δ: 8.86 (d, J=2.7 Hz, 1H), 8.31 (dd, J=2.5, 8.6 Hz, 1H), 7.86 
(d, J=8.5 Hz, 1H), 6.15 (s, 1H), 2.59 (s, 3H), 2.19 (s, 3H). 13C NMR (101 MHz, DMSO) δ: 
166.3, 155.0, 150.2, 147.7, 141.9, 138.6, 127.1, 114.6, 110.3, 15.1, 13.9. HRMS m/z calcd for 
C11H12N4O: 216.1011, found 217.1032 [M + H
+].    
4-(3,5-dimethyl-1H-pyrazol-1-yl)benzimidamide, formate salt (7). Prepared accordingly to 
general method A. 19 mg, 37% yield, white solid. ¹H NMR (400 MHz, D2O) δ: 8.43 (s, 1H), 
7.88 (d, J=8.6 Hz, 2H), 7.58 (d, J=8.9 Hz, 2H), 6.19 (s, 1H), 2.30 (s, 3H), 2.25 (s, 3H). 13C NMR 
(101 MHz, D2O) δ: 170.9, 165.8, 151.3, 143.2, 142.1, 129.0, 126.6, 124.6, 108.1, 12.1, 11.5.  
HRMS m/z calcd for C12H14N4: 214.1218, found 215.1227 [M + H
+].    
6-(2-methylpyrrolidin-1-yl)nicotinimidamide (10). Prepared accordingly to general method B. 
32 mg, 42 % yield, white solid. ¹H NMR (400 MHz, D2O)  δ: 8.40 (d, J=2.6 Hz, 1H), 8.11 (dd, 
J=2.1, 9.7 Hz, 1H), 7.28 - 7.15 (m, 1H), 4.39 (br. s, 1H), 3.83 - 3.76 (m, 1H), 3.58 (br. s, 1H), 
2.32 - 2.14 (m, 3H), 1.96 - 1.90 (m, 1H), 1.29 (d, J=6.4 Hz, 3H). 13C NMR (101 MHz, D2O) δ: 
165.7, 162.5, 139.3, 138.3, 114.0, 111.9, 57.0, 48.2, 31.8, 22.3, 17.2. HRMS m/z calcd for 
C11H16N4: 204.1375, found 205.1359 [M + H
+].    
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6-(3-methylpyrrolidin-1-yl)nicotinimidamide (11). Prepared accordingly to general method B. 
30 mg, 40% yield, white solid. ¹H NMR (400 MHz, D2O)  δ: 8.36 (dd, J=0.6, 2.3 Hz, 1H), 8.06 
(dd, J=2.4, 9.8 Hz, 1H), 7.09 (d, J=9.2 Hz, 1H), 3.79 (br. s, 2H), 3.67 - 3.59 (m, 1H), 3.22 (br. s, 
1H), 2.56 - 2.48 (m, 1H), 2.30 - 2.22 (m, 1H), 1.81 - 1.72 (m, 1H), 1.12 (d, J=7.0 Hz, 3H). 13C 
NMR (101 MHz, D2O) δ: 162.6, 151.1, 139.1, 138.7, 113.5, 111.9, 55.4, 48.2, 32.9, 32.2, 16.4. 
HRMS m/z calcd for C11H16N4: 204.1375, found 205.1367 [M + H
+].    
6-(1H-pyrazol-1-yl)nicotinimidamide, formate salt (13). Prepared accordingly to general 
method A. 16 mg, 37% yield, white solid. ¹H NMR (400 MHz, D2O) δ: 8.79 (d, J=2.0 Hz, 1H), 
8.55 (d, J=3.1 Hz, 1H), 8.44 (s, 1H), 8.32 (dd, J=2.4, 8.7 Hz, 1H), 7.96 (d, J=9.1 Hz, 1H), 7.91 
(d, J=1.6 Hz, 1H), 6.66 (t, J=2.1 Hz, 1H). 13C NMR (101 MHz, D2O) δ: 171.0, 164.0, 153.7, 
147.9, 144.3, 139.5, 129.1, 122.4, 112.7, 109.5. HRMS m/z calcd for C9H9N5: 187.0858, found 
188.0921 [M + H+].    
6-(2-methyl-1H-imidazol-1-yl)nicotinimidamide, formate salt (14). Prepared accordingly to 
general method A. 22 mg, 45% yield, white solid. ¹H NMR (400 MHz, D2O) δ: 8.98 (d, J=2.5 
Hz, 1H), 8.48 (dd, J=2.5, 8.6 Hz, 1H), 7.84 (d, J=8.6 Hz, 1H), 7.62 (d, J=1.7 Hz, 1H), 7.20 (d, 
J=1.7 Hz, 1H), 2.62 (s, 3H). 13C NMR (101 MHz, D2O) δ: 171.0, 163.9, 152.6, 148.3, 146.2, 
140.1, 125.0, 124.5, 120.5, 118.9, 13.3. HRMS m/z calcd for C10H11N5: 201.1014, found 
202.1049 [M + H+].    
6-(2-methylpyrrolidin-1-yl)nicotinonitrile (16). Prepared accordingly to general method C.  72 
mg, 77% yield, white solid. ¹H NMR (400 MHz, CDCl3)  δ: 8.39 (dd, J=0.7, 2.3 Hz, 1H), 7.54 
(dd, J=2.5, 9.0 Hz, 1H), 6.33 (d, J=9.0 Hz, 1H), 4.21 (br. s, 1H), 3.59 - 3.55 (m, 1H), 3.42 - 3.35 
(m, 1H), 2.18 - 2.00 (m, 3H), 1.82 - 1.73 (m, 1H), 1.22 (d, J=6.4 Hz, 3H). 13C NMR (101 MHz, 
 23 
CDCl3) δ: 157.3, 153.2, 139.0, 119.3, 106.3, 94.8, 53.6, 47.2, 32.7, 23.0, 18.9. MS m/z calcd for 
C11H13N3: 187.1, found 188.1 [M + H
+].    
6-(3-methylpyrrolidin-1-yl)nicotinonitrile (17). Prepared accordingly to general method C. 69 
mg, 74% yield, white solid.  ¹H NMR (400 MHz, CDCl3)  δ: 8.39 (dd, J=0.7, 2.3 Hz, 1H), 7.55 
(dd, J=2.3, 8.9 Hz, 1H), 6.31 (dd, J=0.8, 9.0 Hz, 1H), 3.74 - 3.44 (m, 3H), 3.02 (br. s, 1H), 2.46 - 
2.37 (m, 1H), 2.21 - 2.12 (m, 1H), 1.70 - 1.61 (m, 1H), 1.14 (d, J=6.5 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ: 157.6, 153.1, 139.0, 119.2, 106.0, 95.0, 54.0, 46.8, 33.2, 17.9. MS m/z calcd for 
C11H13N3: 187.1, found 188.1 [M + H
+].    
General method A. To a mixture of nitrile (0.24 mmol) and methanol (0.5 mL) in a 
microwave vial equipped with rubber septum and magnetic stirrer, a solution of sodium 
methoxide 0.5 M in methanol (0.5 mL, 0.25 mmol) was added under nitrogen atmosphere. The 
mixture was stirred at room temperature overnight. LC-MS analysis showed complete 
conversion of the nitrile to the imino ether. Ammonium chloride (16 mg, 0.30 mmol) was added 
and the solution was stirred for 8 h at 40 ºC. Solvent was removed under reduced pressure and 
the resulting solid was dissolved in methanol, purified by preparative HPLC (gradient of 5–95% 
acetonitrile in water with 0.1% formic acid over 10 min, flow 25 mL/min) and freeze-dried.   
General method B. A solution of nicotinonitrile 16  or 17 (0. 37 mmol) in methanol (4 mL) 
was treated with gaseous anhydrous hydrochloric acid for 15 minutes at 0 ºC and the reaction 
mixture was left at room temperature for 3 hours. Volatile components were removed by means 
of a nitrogen stream and the resulting solid was dried under vacuum. The white solid was 
dissolved in 2 mL of 7 N ammonia in methanol, transferred in a microwave vial, sealed and left 
at room temperature for 24 hours. The solvent was removed under reduced pressure and the 
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resulting solid was dissolved in methanol, purified by preparative HPLC (gradient of 5–70% 
acetonitrile in water with 0.1% ammonia over 10 min, flow 25 mL/min) and freeze-dried.   
General method C. To a solution of 6-fluoronicotinonitrile (61 mg, 0.5 mmol) in acetonitrile 
(0.5 mL) in a microwave vial, the desired methylpyrrolidine (0.75 mmol) and DIPEA (261 µL, 
1.5 mmol) were added. The tube was sealed and heated at 90 ºC overnight. The solvent and 
volatile components were removed under reduced pressure and the crude mixture was purified 
by FCC over silica using heptane/ethyl acetate (8:2) as eluent mixture.  
 
 Crystallization and structure determination 
The co-crystals were obtained by sitting drop vapor diffusion using 19.5 mg/mL Ube2TΔC 
(residues 1-154) and 5 mM compound 1 in a buffer containing 0.1 M Tris pH 8.0, 0.1 M NaCl, 
0.25 mM TCEP. This solution was mixed 1:1 (1.5 μL + 1.5 μL) with the crystallization buffer 
containing 10% PEG3350, 0.2 M calcium acetate, 0.1 M Tris pH 8.5 and equilibrated against 0.5 
mL of reservoir solution at 20 °C. Crystals appeared within a few hours. Crystals were 
cryoprotected with a solution containing 20% PEG3350, 0.2 M magnesium acetate, 0.1 M Tris 
pH 8.5 and flash frozen in liquid nitrogen. Data were collected at Diamond Light Source (i04-1 
beamline) at 0.9282 Å wavelength and processed using XDS,34 POINTLESS35 and AIMLESS36 
from the CCP4 program suite37 to a resolution limit of 1.85 Å (Table S2). The structure was 
solved by molecular replacement using PDB entry 1YH29 as a search model in MOLREP38. The 
first 32 amino acids were then deleted and manually rebuilt in Coot39 in order to account for the 
domain swap that was unambiguous at such resolution. The domain swapped monomer was used 
again as a search model in MOLREP38 and further refined using Refmac540 and Coot39. The 
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quality of the model was checked using MolProbity.41 Zinc binding sites were validated using 
CheckMyMetal.42 
 
 Zincon assay 
Zincon reagent was prepared by dissolving 4.35 mg of Zincon (Na+ salt) in 200 μL of NaOH 
0.5 M and then diluting it to 5 mL with water. In order to assess zinc contamination we diluted 
this stock solution 1:40 in 50 mM CHES pH 9.0 (orange solution) and added the analyzed 
compound at a final concentration of 2.5 mM. A clear color change to a blue solution was 
appreciable for those compounds contaminated with zinc (Figure 3B). 
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Ube2T, Ubiquitin-conjugating enzyme E2 T; PAINS, pan-assay interference compounds; DSF, 
differential scanning fluorimetry; BLI, bio-layer interferometry; ITC, isothermal titration 
calorimetry; HATU, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid hexafluorophosphate; DIPEA, N,N-diisopropylethylamine; TCEP, tris(2-
carboxyethyl)phosphine; LDS, lithium dodecyl sulfate; SDS-PAGE, sodium dodecyl sulphate - 
 27 
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Figure S1. DSF (A) and BLI (B) results for compound 1. 
 
 
 
 
Figure S2. [15N-1H]-HSQC spectra recorded on 50 μM 15N-Ube2TΔC (blue) and 50 μM 15N-
Ube2TΔC + 500 μM compound 1 (red).  
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Figure S3. DSF results for compounds 13 (A) and 9 (B). (C) ITC titration of 5 mM 9 into 
37.3 μM Ube2T. 
 
 
      
Figure S4. Ube2W domain-swapped crystal structure (PDB entry 2A7L,	Sheng, Y. et al.  
Mol. Cell. Proteomics 2012, 11, 329-341).  
 
 
 
 
Figure S5. Electron density at the two zinc binding sites: (A) Zinc site 1 and (B) Zinc site 2. 
In both panels show the electron density maps before fitting the Zn2+ ion. 2Fo-Fc electron 
density map is contoured at 1.6σ level (grey) around the atoms shown in stick, and Fo-Fc 
electron density map is contoured at 15.0σ level (green). 
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Figure S6. Anomalous difference electron density map at (A) Zinc site 1 and (B) Zinc site 2 
contoured at 3σ. 
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Table S1. ITC data.  
 
 
Syr:Cell 
[Cell] 
(mM) 
[Syr] 
(μM) 
N (sites) KD 
(μM) 
ΔH 
(kcal/mol) 
ΔG 
(kcal/mol) 
-TΔS 
(kcal/mol) 
1:Ube2T 1.5 45.1 1.59 ± 
0.02 
17.7 ± 0.9 -3.60 ± 
0.07 
-6.49 -2.88 
1:Ube2T-
FANCLRING 
1.5 47.3 1.63 ± 
0.02 
21.3 ± 0.7 -3.31 ± 
0.04 
-6.37 -3.06 
ZnCl2:Ube2T 1.5 46.3 1.49 ± 
0.02 
15.7 ± 0.6 -3.93 ± 
0.06 
-6.55 -2.62 
9:Ube2T 5 37.3 fixed to 1 550.0 ± 
89.7 
-7.69 ± 
0.77 
-4.45 3.24 
 
 
 
Table S2. Data Collection and refinement statistics (PDB ID: 5OJJ).  
 
 
Values in parentheses are for the highest resolution shell.  
 
 
 
 
 
 
 
 
Space group P1211 
Molecules/ASU 6 
Cell dimensions   
    a, b, c (Å) 56.02, 96.38, 90.00 
    α, β, γ (°)  90.00, 93.28, 90.00 
Resolution (Å) 48.75 – 1.85 (1.89 – 1.85) 
Total reflections 276408 (13817) 
Unique reflections 81137 (4465) 
Rmerge 0.038 (0.292) 
I/σ(I) 16.6 (3.1) 
CC1/2 0.998 (0.849) 
Completeness (%) 99.7 (99.6) 
Redundancy 3.4 (3.1) 
Rwork / Rfree 0.178/0.199 
No. atoms 8268 
    Protein 7242 
    Water 978 
    Other hetero groups 48 
Average B factor 29.0 
R.m.s. deviations 
    Bond lengths (Å) 0.011 
    Bond angles (°) 1.474 
Ramachandran plot 
Favored (%) 97.53 
Allowed (%) 2.47 
Outliers (%) 0.0 
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NMR spectra of compound 1 as received from commercial source. 
1H-NMR (400 MHz), D2O 
  
13C-NMR (101 MHz), D2O 
 
 
 
HSQC, D2O 
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HRMS data for compound 1 as received from commercial source. 
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SmartFormula Settings
Concentration too high. Dilute sample!
Neutral Loss(es):Adduction(s):
Tolerance mSigma Limit Electron Conf.
20 ppm 60 even
SmartFormula Results
NaFormulaMin: C1H1 FormulaMax:
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# meas. m/z theo. m/z |err| [ppm] mSigma Formula Purity(UVC)[%] Purity(BPC)[%]
2 199.0983 199.0978 2.3 6 C11 H11 N4 0.0 96.3
199.0954 14.4 18 C9 H12 N4 Na
217.1271 5.0 7 C6 H18 N4 Na O3  
217.1282 0.1 9 C7 H21 O7
431.2417 4.0 3 C24 H32 N4 Na O2  
431.2415 3.3 3 C22 H27 N10
3 217.1094 217.1084 4.6 4 C11 H13 N4 O 0.0 3.7
217.1060 15.7 9 C9 H14 N4 Na O
497.1290 0.5 4 C20 H13 N14 O3  
497.1292 0.1 6 C22 H18 N8 Na O5
 
Note: mSigma values <30 indicate high probability of correct molecular formula
Cmpd 1,
1.7 min
Cmpd 2,
1.7 min
Cmpd 3,
2.3 min
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